Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Overview

NASDAQ:SUPN - US8684591089 - Common Stock

46 USD
+0.57 (+1.25%)
Last: 9/5/2025, 8:00:01 PM
46 USD
0 (0%)
After Hours: 9/5/2025, 8:00:01 PM

SUPN Key Statistics, Chart & Performance

Key Statistics
52 Week High46.1
52 Week Low29.16
Market Cap2.58B
Shares56.07M
Float53.74M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)3.26
PE14.11
Fwd PE20.73
Earnings (Next)11-03 2025-11-03/amc
IPO12-28 2010-12-28
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


SUPN short term performance overview.The bars show the price performance of SUPN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

SUPN long term performance overview.The bars show the price performance of SUPN in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of SUPN is 46 USD. In the past month the price increased by 10.95%. In the past year, price increased by 35.93%.

SUPERNUS PHARMACEUTICALS INC / SUPN Daily stock chart

SUPN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.03 688.28B
JNJ JOHNSON & JOHNSON 17.84 429.72B
AZN ASTRAZENECA PLC-SPONS ADR 18.4 253.31B
NVS NOVARTIS AG-SPONSORED ADR 14.66 251.14B
NVO NOVO-NORDISK A/S-SPONS ADR 14.13 245.41B
MRK MERCK & CO. INC. 11 211.59B
PFE PFIZER INC 7.34 141.46B
SNY SANOFI-ADR 10.47 113.41B
BMY BRISTOL-MYERS SQUIBB CO 7 95.95B
GSK GSK PLC-SPON ADR 8.96 81.59B
ZTS ZOETIS INC 24.65 67.95B
TAK TAKEDA PHARMACEUTIC-SP ADR 53.1 48.64B

About SUPN

Company Profile

SUPN logo image Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Company Info

SUPERNUS PHARMACEUTICALS INC

9715 Key West Avenue

Rockville MARYLAND 20850 US

CEO: JACK A. KHATTAR

Employees: 674

SUPN Company Website

SUPN Investor Relations

Phone: 13018382500

SUPERNUS PHARMACEUTICALS INC / SUPN FAQ

What is the stock price of SUPERNUS PHARMACEUTICALS INC today?

The current stock price of SUPN is 46 USD. The price increased by 1.25% in the last trading session.


What is the ticker symbol for SUPERNUS PHARMACEUTICALS INC stock?

The exchange symbol of SUPERNUS PHARMACEUTICALS INC is SUPN and it is listed on the Nasdaq exchange.


On which exchange is SUPN stock listed?

SUPN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SUPERNUS PHARMACEUTICALS INC stock?

11 analysts have analysed SUPN and the average price target is 44.68 USD. This implies a price decrease of -2.88% is expected in the next year compared to the current price of 46. Check the SUPERNUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SUPERNUS PHARMACEUTICALS INC worth?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a market capitalization of 2.58B USD. This makes SUPN a Mid Cap stock.


How many employees does SUPERNUS PHARMACEUTICALS INC have?

SUPERNUS PHARMACEUTICALS INC (SUPN) currently has 674 employees.


What are the support and resistance levels for SUPERNUS PHARMACEUTICALS INC (SUPN) stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a support level at 41.99 and a resistance level at 46.01. Check the full technical report for a detailed analysis of SUPN support and resistance levels.


Is SUPERNUS PHARMACEUTICALS INC (SUPN) expected to grow?

The Revenue of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to grow by 5.81% in the next year. Check the estimates tab for more information on the SUPN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SUPERNUS PHARMACEUTICALS INC (SUPN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SUPERNUS PHARMACEUTICALS INC (SUPN) stock pay dividends?

SUPN does not pay a dividend.


When does SUPERNUS PHARMACEUTICALS INC (SUPN) report earnings?

SUPERNUS PHARMACEUTICALS INC (SUPN) will report earnings on 2025-11-03, after the market close.


What is the Price/Earnings (PE) ratio of SUPERNUS PHARMACEUTICALS INC (SUPN)?

The PE ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.11. This is based on the reported non-GAAP earnings per share of 3.26 and the current share price of 46 USD. Check the full fundamental report for a full analysis of the valuation metrics for SUPN.


What is the Short Interest ratio of SUPERNUS PHARMACEUTICALS INC (SUPN) stock?

The outstanding short interest for SUPERNUS PHARMACEUTICALS INC (SUPN) is 8.75% of its float. Check the ownership tab for more information on the SUPN short interest.


SUPN Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to SUPN. When comparing the yearly performance of all stocks, SUPN is one of the better performing stocks in the market, outperforming 88.03% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SUPN Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to SUPN. SUPN gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SUPN Financial Highlights

Over the last trailing twelve months SUPN reported a non-GAAP Earnings per Share(EPS) of 3.26. The EPS increased by 86.29% compared to the year before.


Industry RankSector Rank
PM (TTM) 9.7%
ROA 4.67%
ROE 6.06%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%150%
Sales Q2Q%-1.71%
EPS 1Y (TTM)86.29%
Revenue 1Y (TTM)5.54%

SUPN Forecast & Estimates

11 analysts have analysed SUPN and the average price target is 44.68 USD. This implies a price decrease of -2.88% is expected in the next year compared to the current price of 46.

For the next year, analysts expect an EPS growth of -14.87% and a revenue growth 5.81% for SUPN


Analysts
Analysts80
Price Target44.68 (-2.87%)
EPS Next Y-14.87%
Revenue Next Year5.81%

SUPN Ownership

Ownership
Inst Owners108.97%
Ins Owners4.08%
Short Float %8.75%
Short Ratio5.46